This page is part of the FHIR Specification (v3.3.0: R4 Ballot 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Ballot Status: Informative |
Definition for Code System ResearchStudyPhase
{ "resourceType": "CodeSystem", "id": "research-study-phase", "meta": { "lastUpdated": "2018-04-03T12:05:46.262+10:00" }, "text": { "status": "generated", "div": "<div>!-- Snipped for Brevity --></div>" }, "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg", "valueCode": "brr" }, { "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-ballot-status", "valueString": "Draft" }, { "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm", "valueInteger": 1 } ], "url": "http://hl7.org/fhir/research-study-phase", "identifier": { "system": "urn:ietf:rfc:3986", "value": "urn:oid:2.16.840.1.113883.4.642.1.822" }, "version": "3.3.0", "name": "ResearchStudyPhase", "status": "draft", "experimental": false, "date": "2018-04-03T12:05:46+10:00", "publisher": "HL7 (FHIR Project)", "contact": [ { "telecom": [ { "system": "url", "value": "http://hl7.org/fhir" }, { "system": "email", "value": "fhir@lists.hl7.org" } ] } ], "description": "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.", "caseSensitive": true, "valueSet": "http://hl7.org/fhir/ValueSet/research-study-phase", "content": "complete", "concept": [ { "code": "n-a", "display": "N/A", "definition": "Trials without phases (for example, studies of devices or behavioral interventions)." }, { "code": "early-phase-1", "display": "Early Phase 1", "definition": "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0." }, { "code": "phase-1", "display": "Phase 1", "definition": "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients." }, { "code": "phase-1-phase-2", "display": "Phase 1/Phase 2", "definition": "Trials that are a combination of phases 1 and 2." }, { "code": "phase-2", "display": "Phase 2", "definition": "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks." }, { "code": "phase-2-phase-3", "display": "Phase 2/Phase 3", "definition": "Trials that are a combination of phases 2 and 3." }, { "code": "phase-3", "display": "Phase 3", "definition": "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug." }, { "code": "phase-4", "display": "Phase 4", "definition": "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use." } ] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.